Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 73.5 EUR 0.55% Market Closed
Market Cap: 1.3B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Pharma Mar SA
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharma Mar SA
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Pharma Mar SA
MAD:PHM
Other Liabilities
€19.3m
CAGR 3-Years
-39%
CAGR 5-Years
55%
CAGR 10-Years
15%
Grifols SA
MAD:GRF
Other Liabilities
€130.7m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Other Liabilities
€3m
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Biotechnology Assets SA
MAD:BST
Other Liabilities
€2.5m
CAGR 3-Years
-33%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
No Stocks Found

Pharma Mar SA
Glance View

Market Cap
1.3B EUR
Industry
Biotechnology

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.

PHM Intrinsic Value
31.23 EUR
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Pharma Mar SA's Other Liabilities?
Other Liabilities
19.3m EUR

Based on the financial report for Sep 30, 2024, Pharma Mar SA's Other Liabilities amounts to 19.3m EUR.

What is Pharma Mar SA's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
15%

Over the last year, the Other Liabilities growth was -31%. The average annual Other Liabilities growth rates for Pharma Mar SA have been -39% over the past three years , 55% over the past five years , and 15% over the past ten years .

Back to Top